Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The only way too see if Sareum is best in class is by results and gauging against the competition, Pfizer CEO has said that their Tyk2 is best in class, and also BMS is saying their pseudo-kinase Tyk2 is the way forward to inhibit Tyk2!
If the judgment is the selectivity the specificity of Tyk2 then Nimbus Tyk2 is more selective in their molecule, just because it is said too be best in class in doesn’t mean it is, it just means it might be best in class, but until it’s in the clinic and can compare results then that is the true representation of the status!
https://imgur.com/a/YtG9Y8V
https://imgur.com/a/gXmHU8o
The share price gains in the pharma sector that I have highlighted are not like for like comparisons with Sareum. What they are illustrating, nonetheless, is that a x 10 or a x 20 rise in our current share price is a distinct prospect given what has transpired in the pharma sector over the past few months. It is definitely down to whether the stars are going to align for Sareum as they have for AVCT, NCYT, SNG, ODX, HEMO etc. For what it is worth, I envisage to see a Hemo style share price rise for Sareum up to 10p. Thereafter if the news flow is encouraging (and frequent) this will take the share price substantially higher in my opinion. Having witnessed this with my investments in NCYT and SNG, in particular, I am a believer in extraordinary share price rises if the science is good. We have been informed in RNS after RNS that we are best in class. Consequently the share price at some stage will deliver the gains we are envisaging. This is undoubtedly reliant on the various news announcements we are all anticipating. i.e.
Covid Grant
Sierra Milestone
Licencing Agreement/s
FLT China Update / Milestone
Lupus News
M&A
Good luck and here’s to the next few weeks, Brighty.
28p is just another term for a party! After the 3p one, 10p one and not sure if theres any more for the over optimistics.
yep 28p was precovid so what the new number is anyones guess
That was Thoth2's calculation of potential value of SAR's molecules to an interested buyer, I believe, although RMM has highlighted other deals that would suggest a much higher figure, and all this before Covid-19 reared its head.
It’s been explained on here numerous times. It is up to you to decide whether or not it is an accurate reflection of the value of the company’s assets.
Where does everyone keep plucking the 28p figure from?
Hasn’t Novacyt got a test kit that’s in production that’s in high demand so there’s not the risk associated with trialing a new molecule too see if it works or not, just because a company is in the same sector that’s had some astounding gains, me myself don’t like comparing a company unless there are striking similarities involved so then you can compare the attributes of that company’s merits like for like, obviously I know this is a chat see and have seen over the years with members posting the companies with high valuations and referring too the company their investing in, could be a dangerous thing too do just because a company works for certain it might not for another, not saying Sareum is one it’s just not prudent to do so!
About December I was at work having a quick skive and making jokes about the company names. One was NCYT I was oh it would be an oversize not to buy that and laughed. Well guess whose laughing now? Not me. Didnt buy any.
Sorry Brighty, what's the significance of the 28p in particular?
Thanks
Once the momentum really kicks in plus FOMO the Sareum share price should replicate the other pharma share gains. For example NCYT hit 1070 today. They were 7p 12 months ago. This illustrates the stratospheric rises that happen in our sector and why the 28p figure (& higher) is certainly possible. Good luck, Brighty